

Product Name: Raltegravir (MK-0518)

Revision Date: 01/10/2021

### **Product Data Sheet**

# Raltegravir (MK-0518)

**Cat. No.:** A4073

CAS No.: 518048-05-0

Formula: C20H21FN6O5


**M.Wt:** 444.4

Synonyms: Raltegravir,MK0518

Target: Proteases

Pathway: HIV Integrase

Storage: Store at -20°C



## Solvent & Solubility

insoluble in EtOH; insoluble in H2O; ≥19.95 mg/mL in DMSO

In Vitro

Preparing Stock Solutions	Solvent  Concentration	1mg	5mg	10mg
	1 mM	2.2502 mL	11.2511 mL	22.5023 mL
	5 mM	0.4500 mL	2.2502 mL	4.5005 mL
	10 mM	0.2250 mL	1.1251 mL	2.2502 mL

Please refer to the solubility information to select the appropriate solvent.

## **Biological Activity**

Shortsummary	HIV-1 integrase inhibitor
IC <sub>50</sub> & Target	

	Cell Viability Assay	Carlos Transfer
	Cell Line:	MT-4 cells
	Preparation method:	The solubility of this compound in DMSO is > 20 mg/mL. General tips for
In Vitro		obtaining a higher concentration: Please warm the tube at 37 °C for 10 minutes
		and/or shake it in the ultrasonic bath for a while. Stock solution can be stored
		below - 20 °C for several months.
	Reacting conditions:	0.0001 ~ 1 μM; 5 days

	Applications:	Raltegravir inhibited SIVmac251 replication at the low nanomolar, the EC50			
		value of which was approximately one order of magnitude lower than that of			
		HIV-1 IIIB. However, HIV-1 exhibited faster cytopathogenicity kinetics than			
		SIVmac251. The results of antigen-capture ELISA assays demonstrated that in			
		human T-cell lines, Raltegravir exhibited similar inhibition on SIVmac251 and			
	210	HIV-1 replication.			
	Animal experiment	Animal experiment			
	Animal models:	SIVmac251-infected rhesus macaques			
	Dosage form:	100 mg; p.o.; b.i.d.			
	Applications:	In SIVmac251-infected rhesus macaques, Raltegravir significantly decreased			
		the viral load, but only in seven days of treatment. One non-human primate			
In Vivo		showed an undetectable viral load after Raltegravir monotherapy. However,			
		this primate had a low viral load before treatment was initiated. In addition, The			
		combination of two NRTIs/NtRTIs plus Raltegravir stably suppressed			
	810	SIVmac251 viral load, but not the proviral DNA, in non-human primates.			
	Other notes:	Please test the solubility of all compounds indoor, and the actual solubility may			
	And the state of t	slightly differ with the theoretical value. This is caused by an experimental			
	3 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	system error and it is normal.			

### **Product Citations**

See more customer validations on www.apexbt.com.

#### References

[1]. Lewis MG1, Norelli S, Collins M, Barreca ML, Iraci N, Chirullo B, Yalley-Ogunro J, Greenhouse J, Titti F, Garaci E, Savarino A. Response of a simian immunodeficiency virus (SIVmac251) to raltegravir: a basis for a new treatment for simian AIDS and an animal model for studying lentiviral persistence during antiretroviral therapy. Retrovirology. 2010 Mar 16;7:21.

#### Caution

#### FOR RESEARCH PURPOSES ONLY.

#### NOT FOR HUMAN, VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

Specific storage and handling information for each product is indicated on the product datasheet. Most APExBIO products are stable under the recommended conditions. Products are sometimes shipped at a temperature that differs from the recommended storage temperature. Shortterm storage of many products are stable in the short-term at temperatures that differ from that required for long-term storage. We ensure that the product is shipped under conditions that will maintain the quality of the reagents. Upon receipt of the product, follow the storage recommendations on the product data sheet.

### **APExBIO Technology**

www.apexbt.com

7505 Fannin street, Suite 410, Houston, TX 77054.

Tel: +1-832-696-8203 | Fax: +1-832-641-3177 | Email: info@apexbt.com



APE BIO

APE BIO

APE BIO

APE BIO

APE BIO

APEVEIO.